黑料网

Metabolomics; Exogenous metabolites; Analytical techniques; Disease monitoring; Drug response

Introduction

Metabolomics, a burgeoning field within clinical pharmacology, offers a comprehensive snapshot of endogenous and exogenous metabolites in biological systems. By studying the metabolic profiles associated with drug exposure and response, metabolomics holds immense potential for advancing our understanding of drug metabolism, efficacy, and toxicity. This article explores the applications of metabolomics in clinical pharmacology, highlighting its role in drug development, personalized medicine, and biomarker discovery [1, 2].

Metabolomics: an overview

Metabolomics involves the systematic analysis of small molecules, or metabolites, present in biological samples such as blood, urine, and tissues. High-throughput analytical techniques, including mass spectrometry and nuclear magnetic resonance spectroscopy, enable the simultaneous detection and quantification of thousands of metabolites. This holistic approach provides insights into cellular processes, biochemical pathways, and metabolic alterations associated with disease states and drug interventions [3].

Unraveling drug metabolism

Metabolomics plays a pivotal role in elucidating the complex pathways of drug metabolism, including phase I and phase II biotransformation reactions. By identifying drug metabolites and their metabolic pathways, metabolomics sheds light on interindividual variability in drug metabolism and pharmacokinetics [4]. Furthermore, metabolomic profiling enables the discovery of biomarkers indicative of drug exposure, metabolism, and therapeutic response, facilitating the optimization of drug dosing regimens and personalized medicine approaches [5].

Pharmacogenomics and metabolomics integration

The integration of metabolomics with pharmacogenomics, the study of genetic factors influencing drug response, holds promise for precision medicine initiatives. By combining information on genetic variations and metabolic phenotypes, researchers can elucidate the mechanisms underlying interindividual variability in drug response [6]. Pharmacometabolomics, a subset of metabolomics, focuses on identifying metabolic signatures predictive of drug efficacy, toxicity, and treatment outcomes. This integrative approach enhances our ability to tailor drug therapy based on individual patient characteristics and genetic profiles [7].

Drug safety and toxicity assessment

Metabolomics provides valuable insights into drug safety and toxicity assessment by identifying biomarkers indicative of adverse drug reactions and organ toxicity. Metabolic profiling enables the early detection of drug-induced metabolic perturbations, facilitating the prediction and mitigation of potential toxicities [8]. Moreover, metabolomic signatures associated with drug-induced liver injury, nephrotoxicity, and cardiotoxicity aid in the development of safer pharmaceuticals and the refinement of preclinical safety assessment strategies [9].

Biomarker discovery and disease monitoring

Metabolomics holds promise for biomarker discovery and disease monitoring across a wide range of therapeutic areas, including oncology, cardiology, and neurology. By identifying disease-specific metabolic signatures, metabolomics enables early disease detection, prognosis assessment, and treatment monitoring. Metabolic biomarkers indicative of disease progression, treatment response, and recurrence risk provide valuable information for clinical decisionmaking and patient management [10].

Conclusion

Metabolomics represents a powerful tool in clinical pharmacology, offering insights into drug metabolism, efficacy, and toxicity across diverse therapeutic areas. By unraveling metabolic pathways, identifying biomarkers, and integrating with pharmacogenomics, metabolomics enhances our understanding of drug response variability and enables personalized medicine approaches. As technologies continue to advance and analytical techniques become more sophisticated, metabolomics will continue to play a pivotal role in shaping the future of drug development and clinical practice.

References

1. Emwas AH, Szczepski K, Poulson BG, Chandra K, McKay RT, et al. (2020) . Molecules 25: 4597.

, ,

2. Li Q, Kang CB (2020) . Molecules 25: 2974.

, ,

3. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, et al. (2008) . Nat Rev Drug Discov 7: 738-745.

, ,

4. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) . Science 274: 1531-1534.

, ,

5. Lamoree B, Hubbard RE (2017) . Essays Biochem 61: 453-464.

, ,

6. Harner MJ, Frank AO, Fesik SW (2013) . J Biomol NMR 56: 65-75.

, ,

7. Li Q (2020) . Front Mol Biosci 7: 180.

, ,

8. Murray CW, Rees DC (2009) . Nat Chem 1: 187-192.

, ,

9. Ayotte Y,  Murugesan JR,  Bilodeau F, Larda S, Bouchard P, et al. (2017) . Protein Sci 26: 194-195.
10. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H (2016) . Nat Rev Drug Discov 15: 605-619.

, ,